Abstract
Oseltamivir is 1 of 2 antiviral medications available for the treatment of influenza B virus infections. We describe and characterize a cluster of influenza B viruses circulating in North Carolina with a mutation in the neuraminidase active site that may reduce susceptibility to oseltamivir and the investigational drug peramivir but not to zanamivir.
MeSH terms
-
Acids, Carbocyclic
-
Adolescent
-
Adult
-
Antiviral Agents / pharmacology
-
Antiviral Agents / therapeutic use
-
Catalytic Domain / genetics
-
Child
-
Child, Preschool
-
Cyclopentanes / pharmacology
-
Cyclopentanes / therapeutic use
-
Drug Resistance, Viral / genetics
-
Guanidines / pharmacology
-
Guanidines / therapeutic use
-
Hemagglutinin Glycoproteins, Influenza Virus / genetics
-
Humans
-
Infant
-
Influenza B virus / classification
-
Influenza B virus / drug effects
-
Influenza B virus / genetics*
-
Influenza, Human / drug therapy
-
Influenza, Human / epidemiology
-
Microbial Sensitivity Tests
-
Middle Aged
-
Mutation*
-
Neuraminidase / genetics*
-
North Carolina / epidemiology
-
Oseltamivir / pharmacology
-
Oseltamivir / therapeutic use
-
Phylogeny
-
Polymorphism, Single Nucleotide
-
Young Adult
Substances
-
Acids, Carbocyclic
-
Antiviral Agents
-
Cyclopentanes
-
Guanidines
-
Hemagglutinin Glycoproteins, Influenza Virus
-
Oseltamivir
-
Neuraminidase
-
peramivir